Novo Holdings Leads $50M Growth Investment in MedGenome

Novo Holdings to Acquire Benchmark Genetics

November 25, 2024

Biotechnology

Novo Holdings agreed to acquire Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million. Completion is expected in the first quarter of 2025, subject to shareholder approval and regulatory clearances, with initial consideration of £230 million plus up to £30 million contingent on revenue thresholds.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novo Holdings Invests in Manipal Hospitals

February 6, 2024

Healthcare Services

Novo Holdings has made an investment in Manipal Hospitals, a leading private hospital chain in India — Novo Holdings' largest investment in Asia to date. Manipal operates a network of hospitals (33 sites, ~9,500+ beds) and a large medical staff (5,000+ doctors), and the investment is intended to support Manipal's next phase of growth and expansion of high-quality, affordable healthcare across India.

Novo Holdings Acquires Medical Knowledge Group

January 3, 2022

Healthcare Services

Novo Holdings A/S has agreed to acquire Medical Knowledge Group (MKG) from Court Square Capital and Aisling Capital. MKG is an analytics-driven, technology-enabled drug commercialisation and medical communications platform headquartered in New York with more than 500 employees; Novo said the acquisition will support MKG's continued growth in biopharmaceutical commercialisation services.

Novo Holdings Invests $72 Million in LanzaTech

August 6, 2019

Biotechnology

Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.

Novo Holdings Invests in Oxford Biomedica plc

May 28, 2019

Biotechnology

Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.